Drug comparisons
Saxagliptin vs Pioglitazone
Saxagliptin vs Pioglitazone: DPP-4 inhibitor vs TZD for type 2 diabetes. Compare heart failure risks, weight gain, edema, insulin resistance, and side effects.
No comparison dimensions are available for this page.
Clinical context
This comparison is triggered when type 2 diabetes patients on metformin require add-on oral therapy and must balance DPP-4 incretin effects against TZD insulin-sensitizing benefits amid cardiovascular and fluid-retention concerns.
Bottom line
Saxagliptin generally suits patients prioritizing weight neutrality and lower edema risk, while Pioglitazone may be considered for significant insulin resistance, with neither inherently superior and selection based on individual risk profiles.
All medication comparisons